Comparative Pharmacology
Head-to-head clinical analysis: PRAMIPEXOLE DIHYDROCHLORIDE versus REQUIP XL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PRAMIPEXOLE DIHYDROCHLORIDE versus REQUIP XL.
PRAMIPEXOLE DIHYDROCHLORIDE vs REQUIP XL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-ergoline dopamine agonist that selectively binds to D2 and D3 dopamine receptors, particularly D3, in the striatum and substantia nigra, mimicking dopamine's effects to improve motor function in Parkinson's disease.
Ropinirole is a non-ergoline dopamine agonist with high relative in vitro specificity and full intrinsic activity at the D2 subfamily of dopamine receptors, binding with higher affinity to D3 than to D2 or D4 receptor subtypes. The relevance of D3 receptor binding in Parkinson's disease is unknown.
0.125 mg orally three times daily, titrated as tolerated to maximum 4.5 mg/day
Initial: 2 mg orally once daily for weeks 1-2, then titrate as needed; maintenance: 8-24 mg orally once daily.
None Documented
None Documented
Terminal half-life: 8–12 hours in young adults; up to 15–18 hours in elderly. Clinical context: Once-daily dosing; steady-state in 2–4 days.
Approximately 6 hours (range 4-8 hours) for ropinirole; terminal half-life in elderly or hepatic impairment may be prolonged up to 10-12 hours. Clinically, steady-state achieved within 2 days of dosing.
Renal: ~90% unchanged in urine; biliary/fecal: ~2%.
Renal: 60% (mainly metabolites, <10% unchanged); fecal/biliary: 20%; total excretion accounts for >80% of dose.
Category A/B
Category C
Dopamine Agonist
Dopamine Agonist